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Abstract
Background: Patients with allergic rhinitis often trivialise their condition, self-manage inappropriately, and would
benefit from health care intervention. The primary point of health care contact for these self-managing allergic
rhinitis patients is the community pharmacy. With the majority of allergic rhinitis treatments being available for
purchase over the counter, without health care professional contact, we know little about how the patients self-
manage. This study aims to identify the burden of allergic rhinitis in the community pharmacy and to identify key
opportunity for intervention.
Methods: Pharmacy customers, who purchased nasal treatment in a community pharmacy, were approached with
a research-administered questionnaire that collected data on medical history, symptoms and products purchased
for the treatment of nasal symptoms.
Results: Of the 296 participants, 69.9% self-managed with over-the-counter medications; with 68% experiencing
allergic rhinitis symptoms and only 44.3% of this subgroup had a doctor’s diagnosis. Nasal congestion (73.6%) was
most commonly experienced and oral antihistamines were most commonly purchased (44.3%), indicating a pattern
of suboptimal management. A third of participants (36.5%) experienced moderate-severe symptoms, persistently,
which impacted on their daily living. Medication selection was mainly based on pharmacy customers’ perceptions
of medication effectiveness (47.6%).
Conclusion: A majority of participants that self-selected over-the-counter medications have symptoms consistent
with allergic rhinitis, with almost half not having received a diagnosis. Medication purchasing patterns suggest that
sub-optimal therapeutic decisions made by participants, even when they are experiencing significant symptoms.
This study uncovers the hidden burden of allergic rhinitis in the community pharmacy and a missed opportunity to
intervene and refer if necessary. Patients need to be guided through appropriate treatment as this study showed
that many should be referred to a medical practitioner.
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Background
Allergic Rhinitis(AR) is a chronic respiratory condition
characterised by sneezing, itching, rhinorrhoea and nasal
congestion [1], induced by IgE-mediated inflammation
in the nose, in response to allergens [1]. Although AR
shares similar nasal symptoms with non-AR or
rhinosinusitis [2], it is a distinct chronic disease of
the upper airways, which is not a minor ailment. AR
currently affects 10–30% of the world’s population [3]
and the prevalence is still increasing [1]. It presents a
significant health burden especially when it is uncon-
trolled [1], impairing an individual’s day-to-day activities,
causing sleep disturbance resulting in daytime fatigue and
affecting work productivity [1, 4, 5]. The ramifications
of poorly controlled AR extend into other disease
states, most notably asthma, where the likelihood of
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exacerbations or flare-ups is elevated [1]. Given that ap-
proximately 50% of people with asthma have poorly
controlled disease [6], the importance of treating coex-
isting AR is paramount [1].
Differential diagnosis of AR from other forms of rhin-
itis is not easily defined as AR rarely presents in isolation
[7]. This complicates the management of AR [2] yet
many sufferers are still self-selecting in the community
pharmacy [8]. To optimise self-selection of AR medication,
patients would ideally have received a diagnosis from a
health care professional (HCP) and are able to determine
the appropriateness of medication from the manufacturer’s
written information [9]. In theory this may seem feasible,
however many with nasal symptoms do not seek diagnosis
or advice [10]. Given that the management of AR is not
straightforward, it requires proper medical guidance for
self-management, in order to ensure that optimise
treatment outcomes are achieved [1].
In Australia, many of the AR treatments are ‘pharmacy
medicines’, ‘Schedule 2’, stored on open shelves and avail-
able over the counter (OTC), without prescription and
without the requirement of pharmacist intervention [11].
Patients seeking to purchase AR treatments in the com-
munity pharmacy do so without consulting a pharmacist
[8] although pharmacists are accessible [12], they are
underutilised [13]. Patients tend to perceive their illness to
be a ‘minor’ ailment, which they can easily, manage
themselves [10]. The ease of medication accessibility
[14], their lack of awareness of importance of appropriate
treatment [15] and their low expectation of the pharmacist
[16], could be the potential reasons for patient interactions
with pharmacists to be less than ideal [17].
In order to optimise the management of AR in the
community, it is important to understand to what extent
people with AR self manage and why. With AR treatments
being available over the counter in pharmacies, the burden
is hidden and hence we are unable to identify opportun-
ities to intervene and optimise management. Therefore,
this study aims to identify patients who self-select and self
manage their AR within a community pharmacy setting,
in order to gain an appreciation of the burden on phar-
macy and also identify opportunities where pharmacists
can intervene to deliver health care interventions and op-
timise AR management.
Methods
This research took the form of a cross-sectional obser-
vational study of pharmacy customers purchasing
treatments for nasal symptom(s) from community
pharmacies during July–September 2015 (Australian
spring) and April–June 2016 (Australian autumn). All
participants provided informed consent prior to enrol-
ling in the study.
Participants and setting
Community pharmacies within the Sydney metropolitan
area, which had expressed an interest in research or
pharmacy services, were approached to participate in
this research. The sample of pharmacists approached to
participate were strategically chosen to ensure that
pharmacies covered a spectrum of socio-demographic
locations. Participation in the study involved giving per-
mission for the researcher to conduct a survey with
customers who fulfilled the inclusion criteria and did
not violate the exclusion criteria, within the community
pharmacy setting.
The inclusion criteria for study participants were as
follows: pharmacy customers who visited the pharmacy
and independently self-selected OTC treatment(s) for
nasal symptom(s) without pharmacist advice; or consulted
the pharmacist for advice regarding treatment(s) for nasal
symptom(s); or consulted the pharmacist requesting a
specific treatment for nasal symptom(s); or presented a
prescription for treatment of nasal symptom(s) (Fig. 1).
Pharmacy customers were included in the study if they
were purchasing treatments for themselves or for other
family members and had the knowledge to answer the
questions on behalf of that family member. Pharmacy
customers were excluded from the study if they were
purchasing treatments other than for nasal symptoms
or were unable to answer questions relating to the pur-
chase of the product when purchasing for another fam-
ily member or someone else.
Survey
A researcher-administered structured questionnaire was
developed based on published literature, the research and
practice expertise of the investigators and the framework
of current international guidelines for the management of
AR(1) (Additional file 1). The study questionnaire covered
three domains: i) demographic characteristics (age, gender,
who the medication was for, method of product selection,
diagnosis), ii) nasal (clinical) symptoms for which the
product was being purchased (nature, frequency, duration
and severity of symptoms, and triggers) and iii) manage-
ment of nasal symptoms (treatment purchased) (Fig. 2).
Based on the literature it was expected that a cohort of
patients would be seeking treatment for AR, despite
not previously being diagnosed by a doctor, therefore,
in order to describe the study population as accurately
as possible, three clinical experts evaluated the poten-
tial presence of AR based on patient reported nasal
symptoms and triggers identified [18]. With the data
collected the expert clinical panel determined whether
presenting nasal symptoms were related to AR, viral in-
fections such as a common cold/flu, or other known or
unknown causes. Based on the reported prevalence of
self-selection medication for AR, a sample of 200 AR
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patients was required to achieve a representative
sample [19].
Data analysis
All data collected were de-identified. Data were analysed
using SPSS (IBM® SPSS® Statistics) Version 22. Descrip-
tive statistics were used for continuous and categorical
variables.
Results
Each pharmacy that was approached to participate in the
study, agreed to do so. A total of 8 pharmacies were re-
cruited and of the 419 pharmacy customers approached
by the researcher, 296 met the inclusion criteria and
agreed to participate. Reasons for non-participating are
summarised in Fig. 2. Of the 296 participants, 17.9%
(53/296) were purchasing nasal treatments for other
family members and could provide a full account of the
nature of the condition.
Table 1 summarises the clinical characteristics of par-
ticipants self-selected against those who consulted a
pharmacist. Sixty-three percent (187/296) of the partici-
pants had a doctor’s diagnosis for their presenting nasal
symptoms. A total of 67.9% (201/296) were classified as
having AR (Table 1), of which 65.2% (131/201) had a
doctor’s diagnosis and 35.3% (71/201) were identified by
the expert clinical panel. Others (14.2%, 42/296) included
a combination of non-allergic rhinitis, sinusitis, postnasal
drip and those who are unidentifiable (8.4%, 25/296) in-
cluded a range of nasal symptoms for which a definitive
cause of symptoms could not be determined without
further referral to a medical practitioner.
Rhinorrhoea and nasal congestion were most commonly
experienced (Table 1). A majority of symptoms were expe-
rienced to a moderate-severe extent (Table 1), persistently
for the majority of participants with AR (55.7%, 112/201)
and intermittently for the majority of the participants with
cold/flu (71.4%, 20/28) (Fig. 3). The majority of partici-
pants who reported wheezing also had AR (84.2%, 32/38).
Fig. 1 Study design overview
Fig. 2 Inclusion of participants with nasal symptoms in the study (n = 296)
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When participants were asked “what symptoms is this
product(s) being used to treat?”, 51.7% (153/296) reported
only one symptom. On further questioning, 48.3%
(143/296) reported more than one symptom; with 57.7%
(116/201) of the AR participants underreporting the
number of symptoms experienced.
Of the participants that reported an impact of symp-
toms on their quality of life (QOL), the most recognisable
Table 1 Demographics and clinical characteristics of participants (n = 296)
Variable All participants
(n = 296)
Self-selected OTC
treatment(s) (n = 206)
Consulted with the Pharmacist (n = 90)
Product based request
(n = 42)
Symptom based request
(n = 30)
Prescribed treatment
(n = 18)
Gender
Female 197 (66.6%) 142 (68.9%) 21 (50.0%) 22 (73.3%) 12 (66.7%)
Male 99 (33.4%) 64 (31.1%) 21 (50.0%) 8 (26.7%) 6 (33.3%)
Age group
< 18 20 (6.8%) 15 (7.3%) 3 (7.1%) 0 (0%) 2 (11.1%)
18–39 102 (34.5%) 72 (35.0%) 12 (28.6%) 8 (26.7%) 10 (55.6%)
> 40 174 (58.8%) 119 (57.8%) 27 (64.3%) 22 (73.3%) 6 (33.3%)
Differential diagnosis
AR 201 (67.9%) 139 (67.5%) 31 (73.8%) 16 (53.3%) 15 (83.3%)
Cold/Flu 28 (9.5%) 22 (10.7%) 2 (4.8%) 3 (10.0%) 1 (5.6%)
Other 42 (14.2%) 31 (15.0%) 4 (9.5%) 5 (16.7%) 2 (11.1%)
Unidentifiable 25 (8.5%) 14 (6.8%) 5 (11.9%) 6 (20.0%) 0 (0%)
Symptoms
Sneezing 198 (66.9%) 139 (67.5%) 28 (66.7%) 18 (60.0%) 13 (72.2%)
Rhinorrhoea 212 (71.6%) 147 (71.4%) 31 (73.8%) 20 (66.7%) 14 (77.8%)
Nasal Congestion 218 (73.6%) 149 (72.3%) 31 (73.8%) 23 (76.7%) 15 (83.8%)
Itchy Nose 81 (27.4%) 64 (31.1%) 9 (21.4%) 3 (10.0%) 5 (27.8%)
Itchy Eyes 151 (51.0%) 110 (53.4%) 22 (52.4%) 12 (40.0%) 7 (38.9%)
Itchy Ears/palate 55 (18.6%) 41 (19.9%) 6 (14.3%) 4 (13.3%) 4 (22.2%)
Wheeze 37 (12.5%) 32 (15.5%) 2 (4.8%) 0 (0%) 3 (16.7%)
Headache 28 (9.5%) 22 (10.7%) 2 (4.8%) 2 (6.7%) 2 (11.1%)
Fever 6 (2.0%) 5 (2.4%) 0 (0%) 1 (3.3%) 0 (0%)
Duration of Symptoms
Intermittent 144 (48.7%) 96 (46.9%) 22 (52.4%) 16 (53.5%) 10 (55.6%)
Persistent 152 (51.4%) 110 (53.4%) 20 (47.5%) 14 (46.7%) 8 (44.4%)
Severity of symptoms
Mild 31 (10.5%) 25 (12.1%) 4 (9.5%) 2 (6.7%) 0 (0%)
Moderate-Severe 265 (89.5%) 181 (90.5%) 38 (90.5%) 28 (93.3%) 18 (100%)
Impact of symptoms on QOL
Daily activities 111 (37.5%) 68 (33.0%) 19 (45.2%) 12 (40.0%) 12 (66.7%)
Performance 27 (9.1%) 15 (73%) 4 (9.5%) 3 (10.0%) 5 (27.8%)
Sleep 79 (26.7%) 58 (28.2%) 10 (23.8%) 5 (16.7%) 6 (33.3%)
None 118 (39.9%) 96 (46.6%) 10 (23.8%) 11 (36.7%) 1 (5.6%)
Triggers of symptoms
Identified 180 (60.8%) 130 (63.1%) 27 (64.3%) 11 (36.7%) 12 (66.7%)
Onset period of symptoms
Seasonal 149 (50.3%) 105 (51.0%) 27 (64.3%) 9 (30.0%) 8 (44.4%)
Year Round 67 (22.6%) 55 (26.7%) 3 (7.1%) 7 (23.3%) 2 (11.1%)
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impact was on daily activities (Table 1). Fourteen percent
(42/296) of participants reported impact on more than
one aspect of their QOL.
The majority of the participants identified a trigger
that worsened their symptoms (Table 1), and 23.3% (69/
296) identified more than one. For the AR participants,
the most common outdoor allergen reported was pollen
(54.7%, 110/201) and indoor allergen was house dust
mite (34.3%, 69/201). More than half of the AR partici-
pants attributed their onset of symptoms to a seasonal
basis (Table 1).
Table 2 summarises the various medications purchased
by participants. Oral antihistamines and intranasal corti-
costeroids were most commonly purchased to treat AR
(89% and 77% respectively). The majority of participants
with cold/flu purchased intranasal decongestants or saline
(Table 2). Figure 4 compares the proportion of medica-
tions purchased via self-selection or consulted with the
pharmacist, which includes medications with a prescrip-
tion. There was statistically significant difference between
the proportion of participants who purchase an intranasal
corticosteroid when comparing participants who con-
sulted with the pharmacist, compared with those who
self-selected (38.9% vs 21.4% respectively, χ2 = 9.837, p =
0.003) but there was no statistically significant difference
between the proportion of participants who purchase an
oral antihistamine when comparing participants who
consulted with the pharmacist, compared with those
who self-selected (42.2% vs 43.7% respectively, χ2 = 0.055,
p = 0.899).
Forty-eight percent (141/296) of the participants self-
selected their medications based on their perception of
medication effectiveness. The next common reason was
based on HCP’s recommendation (13.5%, 40/296), followed
closely by interaction with a pharmacist (15.5%, 46/296).
There were also other reasons (16.9%, 56/296) which
included price concern, instructions written on the pack-
age, recommended by family or friend, advertisement,
ingredient preference and seeking others of the same class
of drugs.
Discussion
This study identified that there is a substantial, hidden
burden of AR in community pharmacy. Just under three
quarters of participants self-selected their product, based
on the patient’s perception of what they felt was most ef-
fective. Amongst those who consulted the pharmacist,
almost half of them had a product request; only a third a
symptom request and a fifth of them came with a pre-
scription. More than half the participants who come into
the pharmacy to treat nasal symptoms had AR and a
striking 56% of these patients did not have a HCP diag-
nosis of AR; even though the majority were experiencing
moderate-severe symptoms, on a persistent basis. The
most common symptom experienced was nasal conges-
tion, however the most common therapeutic class of
treatment purchased was oral antihistamine, which does
not address congestion. These results highlight the need
for pharmacist intervention in selecting medication for
the treatment of nasal symptoms.
AR was the most common condition experienced by
participants seeking treatment for nasal symptoms. Only
half the participants had a diagnosis, a trend that has
existed for years (7, 20). While there are guidelines that
base the diagnosis of AR on symptoms history with al-
lergy confirmation via a skin prick test or radioallergo-
sorben (RAST) test [1]; patients are not consulting the
HCP, therefore these guidelines should be tailored to real
life health behaviours. Since this study showed that with
appropriate questioning, a pharmacist is able to identify
patients with a high likelihood of having AR, pharmacy
intervention, in the form of risk assessment or a screen
tool are required. In fact, the process used to identify
and clarify the cause of nasal symptoms in this study
suggest that implementation of such tools would be feas-
ible for use in the community pharmacy setting.
70%
64%
100%
56%
72%
71%
20%
19%
0%
19%
7%
13%
10%
11%
11%
15%
11%
0%
6%
14%
6%
5%
Oral Decongestant (n=20)
Saline (n=36)
Intranasal Antihistamine (n=1)
Intranasal Corticosteroid (n=79)
Intranasal Decongestant (n=54)
Oral Antihistamines (n=131)
Self-selected Symptom-based request Product-based request Prescribed treatment
Fig. 3 Proportion of products purchased by various management methods (n = 296) (Percentage of participants)
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Pharmacists are also in a position to identify patients
that do require referral. While a majority, either through
previous diagnosis or pharmacist questioning were able
to have the cause of their nasal symptoms identified, 25
participants required immediate referral to the doctor,
for symptoms which could not be attributed to obvious
causes. This highlights the importance of pharmacist’s
engagement with patients, even for what are perceived
to be trivial symptoms. Despite the common prevalence
of nasal symptoms, they can be presented in a complex
way and be indicative of a more complex condition.
Pharmacists need to have the opportunity to identify
those patients who need immediate referral to a doctor.
In addition to participants’ poor perception of the ‘ser-
iousness’ of their AR (given the severity of symptoms expe-
rienced by majority of the participant), they also seem to
have a superficial perception of the extent of symptoms ex-
perienced. Patients seemed to focus on one key symptom,
often fail to mention the range of symptoms they were
experiencing except upon in-depth questioning. This
has important implications for treatment option as with
the combination of patients underestimating their con-
dition [20] and poorly perceiving their symptoms [21],
there is a potential for delayed diagnosis. Therefore, this
indicates the importance the role of community pharma-
cists in the management of AR.
This study also suggests that patients may overestimate
their self-management ability. They recognised their pri-
mary symptoms and noted an impact on their day-to-day
living, yet did not see the need to seek medical attention,
even when the impact on their day-to-day living was sig-
nificant. This indicates that there is a disconnection be-
tween patient experiences of symptoms and their health
behaviours, resulting in the inappropriate selection of
products. Participants relied on their perception of medi-
cation effectiveness, which is consistent with the Health
Belief Model (HBM) [22], rather than what is clinically
known to be the optimal treatment. HBM states that self-
management behaviour is driven by patient’s perceived
susceptibility (the threat of getting a disease before they
take the next step in management) perceived severity of
the condition (realisation of the severity of disease before
consulting a health care professional), perceived benefits
of treatment and perceived barriers or potential adverse
effects resulting from their actions [22]. This re-iterates
the importance of HCPs’ advice which enables patients
to fully comprehend the correct use of medication [23].
It could also provide a solution to the trend observed
in the management of AR i.e. for patients to keep search-
ing for more effective medications for AR, as they are not
satisfied with their current treatment [24].
These results have clinical implications especially for
participants with AR. This study showed the feasibility
Table 2 Therapeutic classes of treatments purchased by participants (n = 296)
Therapeutic classes All participants
(n = 296)
Self-selected OTC
treatment(s) (n = 206)
Consulted with the pharmacist (n = 90)
Product-based request
(n = 42)
Symptom-based request
(n = 30)
Prescribed treatment
(n = 18)
Purchased Medication
Oral Antihistamine 131 (44.3%) 93 (45.1%) 17 (40.5%) 14 (46.7%) 7 (38.9%)
Intranasal Decongestant 54 (18.2%) 39 (18.9%) 4 (9.5%) 8 (26.7%) 3 (16.7%)
Intranasal Corticosteroids 79 (26.7%) 44 (21.4%) 15 (35.7%) 9 (30.0%) 11 (61.1%)
Intranasal Antihistamine 1 (0.3%) 1 (0.5%) 0 (0%) 0 (0%) 0 (0%)
Saline 36 (12.2%) 23 (11.2%) 7 (16.7%) 4 (13.3%) 2 (11.1%)
Oral Decongestant 20 (6.8%) 14 (6.8%) 4 (9.5%) 2 (6.7%) 0 (0%)
AR Intermittent
30%
Other 
Intermittent
11%
Cold/Flu 
Intermittent
7%Cold/Flu 
Persistent
2%
Other 
Persistent
11%
AR Persistent
39%
Fig. 4 Proportion of participants experiencing intermittent or persistent
symptoms (n = 296). *Other participants = alternative diagnosis,
non-allergic rhinitis or unable to determine diagnosis
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of a pharmacist-implemented tool to identify the cause
of nasal symptoms within a community pharmacy set-
ting. There is a critical necessity for pharmacists to
identify patients with chronic upper airway disease so
that they can receive appropriate treatment. This is par-
ticularly important for the management of AR. This study
showed that intranasal corticosteroids were preferred over
oral antihistamine to treat AR, for participants who con-
sulted with the pharmacist. This treatment selection is in
accordance with the international guideline – Allergic
Rhinitis and its impact on Asthma (ARIA) guideline [25].
ARIA guidelines developed over the past 20 years have
improved the care of AR patients [25]. Participants who
obtained professional advice from a pharmacist had a
higher chance of choosing the recommended medication
for their condition. Pharmacist are well placed to identify
the symptoms of AR and recommend appropriate OTC
treatment, and therefore important in many areas of inter-
vention in AR.
While a potential limitation of this study is the non-
random nature of the selection of pharmacies into this
study, this descriptive study provides a significant evi-
dence to target further exploration into the way in which
pharmacists can better engage with patients purchasing
OTC products for the treatment of AR. Patients are
clearly at risk of suboptimal or inappropriate manage-
ment based on patient self-perceived effectiveness and
self-selection of products for AR, this can have signifi-
cant impact on co-morbidities, in particular asthma.
Conclusion
In conclusion, this research confirms that the level of
self-management of AR in the community pharmacy is
high, that pharmacist engagement is low and that there
is a significant missed opportunity to ensure that opti-
mal management of AR with OTC products is enabled.
This study indicates that as a result of patients driving
their own treatment, that burden of AR in community
pharmacy is not only high, but also hidden. This is par-
ticularly important when we consider that a majority of
these patients are attempting to self-treat AR without a
diagnosis or HCP input, even when they may have a co-
existing asthma. In order to ensure referral to a doctor is
made in a timely manner for patients with AR and sub-
sequent appropriate OTC treatment is being selected,
pharmacists need to be up skilled in this area of care,
and they need to be provided with tools e.g. screening
tools, risk assessment tools. Future research needs to ex-
plore ways in which guideline-driven clinical pathways
can be implemented and evaluated in the community
pharmacy setting. It may be that this is potentially one
of the most effective ways of controlling AR-relate co-
morbidities, such as asthma in the future.
Additional file
Additional file 1: Researcher administered survey (DOCX 21 kb)
Acknowledgements
Not applicable
Funding
Not applicable.
Availability of data and materials
Not applicable
Authors’ contributions
RT collected the data, analysed and interpreted it by discussing with SB-A,
BC, KY and VK. RT also wrote the draft for the manuscript. SB-A, PS and DP
contributed to the design of the study. BC contributed in the design of the
study, and assisted with the ethical approval of the study. BC also contributed
in analysing and interpreting the data, and reviewing various drafts of the
manuscript. VK mainly assisted in the interpretation of data and discuss the way
the data is to be expressed, through reviewing drafts of the manuscript. KY
made some critical decisions in data that was complicated, mainly giving advice
on the interpreting the data from a clinical perspective; while contributing ideas
in writing the manuscript. SB-A supervised the research, making final decisions
on the way the data was to be analysed and interpreted and was also
heavily involved in reviewing the drafts of manuscripts. All authors revised
the manuscript critically for important intellectual content and also approved
the final version.
Ethics approval and consent to participate
Ethics approval was obtained by the University of Sydney Human Research
Ethics Committee (Reference No. 2015/527).
Consent for publication
Not applicable
Competing interests
The authors involved in this research are Rachel Tan, Biljana Cvetkovski, Vicky
Kritikos, David Price, Kwok Yan, Pete Smith and Sinthia Bosnic-Anticevich.
Rachel Tan and Biljana Cvetkovski declare that they have no competing
interest. Vicky Kritikos has received honoraria from AstraZeneca, GlaxoSmithKline
and Pfizer. Kwok Yan has received honoraria for speaking and consulting from
AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Meda, Mundipharma and
Pfizer. Pete Smith is a clinical allergist with research and clinical interest in
rhinology and has also been a speaker for Meda, GlaxoSmithKline, Novartis,
Mundipharma and AstraZeneca. David Price has board membership with
Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Meda,
Mundipharma, Napp, Novartis, and Teva Pharmaceuticals; consultancy
agreements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim,
Chiesi, GlaxoSmithKline, Meda, Mundipharma, Napp, Novartis, Pfizer, Teva
Pharmaceuticals, and Theravance; grants and unrestricted funding for
investigator-initiated studies (conducted through Observational and
Pragmatic Research Institute Pte Ltd) from UK National Health Service,
British Lung Foundation, Aerocrine, AKL Research and Development Ltd.,
AstraZeneca, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp,
Novartis, Pfizer, Respiratory Effectiveness Group, Takeda, Teva Pharmaceuticals,
Zentiva, and Theravance; payment for lectures/speaking engagements from
Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline,
Kyorin, Meda, Merck, Mundipharma, Novartis, Pfizer, Skyepharma, Takeda, and
Teva Pharmaceuticals; payment for manuscript preparation from Mundipharma
and Teva Pharmaceuticals; payment for the development of educational
materials from Novartis and Mundipharma; payment for travel/accommodation/
meeting expenses from Aerocrine, Boehringer Ingelheim, Mundipharma, Napp,
Novartis, Teva Pharmaceuticals, and AstraZeneca; funding for patient enrolment
or completion of research from Chiesi, Teva Pharmaceuticals, Zentiva, and
Novartis; stock/stock options from AKL Research and Development Ltd.,
which produces phytopharmaceuticals; owns 74% of the social enterprise
Optimum Patient Care Ltd., UK, and 74% of Observational and Pragmatic
Research Institute Pte Ltd., Singapore; and is peer reviewer for grant
committees of the Medical Research Council, Efficacy and Mechanism
Tan et al. Asthma Research and Practice  (2017) 3:8 Page 7 of 8
Evaluation programme, and Health Technology Assessment. Sinthia Bosnic-
Anticevich is a member of the Teva Pharmaceuticals Devices International
Key Experts Panel, has received research support from Research in Real Life, has
received lecture fees and payment for developing educational presentations
from Teva and Mundipharma; and has received Honoria from AstraZeneca,
Boehringer Ingelheim, GlaxoSmithKline, for her contribution to advisory
boards/key international expert forum.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Quality Use of Respiratory Medicines Group, Woolcock Institute, University
of Sydney, Sydney, Australia. 2Academic Primary Care, University of
Aberdeen, Aberdeen, UK. 3Observational and Pragmatic Research Institute
Pte Ltd, Singapore, Singapore. 4Royal Prince Alfred Hospital, Sydney, Australia.
5Clinical Medicine, Griffith University, Southport, QLD, Australia. 6Sydney Local
Health District, Sydney, Australia.
Received: 23 July 2017 Accepted: 7 November 2017
References
1. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A,
Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, et al. Allergic rhinitis
and its impact on asthma (ARIA) 2008 update (in collaboration with the World
Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8–160.
2. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, Cohen N,
Cervin A, Douglas R, Gevaert P et al: European Position Paper on Rhinosinusitis
and Nasal Polyps 2012. Rhinol Suppl 2012(23):3 p preceding table of contents,
1–298.
3. Pawankar R, Canonica R, Holgate S, Lockey R, Blaiss M. World allergy
organisation (WAO) white book on allergy: update 2013. Milwaukee: World
Allergy Organization; 2013.
4. Keith PK, Desrosiers M, Laister T, Schellenberg RR, Waserman S. The burden
of allergic rhinitis (AR) in Canada: perspectives of physicians and patients.
Allergy Asthma Clin Immunol. 2012;8(1):7.
5. Pawankar R, Canonica G, Holgate S, Loceky R. World Allergy Organisation
(WAO): White book on allergy. Wisconsin: World Allergy Organisation; 2011.
Available online at: http://www.worldallergy.org/UserFiles/file/WAO-White-
Book-on-Allergy_web.pdf.
6. Reddel HK, Bateman ED, Becker A, Boulet L-P, Cruz AA, Drazen JM, Haahtela T,
Hurd SS, Inoue H, de Jongste JC. A summary of the new GINA strategy: a
roadmap to asthma control. Eur Respir J. 2015;46(3):622–39.
7. Hadley J, Derebery M, Marple B. Comorbidities and allergic rhinitis: not just
a runny nose. The Journal of family practice. 2012;61(2 Suppl):S11–5.
8. Williams A, Scadding G. Is reliance on self-medication and pharmacy care
adequate for rhinitis patients? Int J Clin Pract. 2009;63(1):98–104.
9. Brass E, Shay L, Leonard-Segal A. Analysis of multiple end points in consumer
research in support of switching drugs from prescription to over-the-
counter status: the concept of end-point hierarchies. Clin Pharmacol Ther.
2009;85(4):369–74.
10. Fromer LM, Blaiss MS, Jacob-Nara JA, Long RM, Mannion KM, Lauersen LA.
Current allergic rhinitis experiences survey (CARES): Consumers' awareness,
attitudes and practices. Allergy Asthma Proc. 2014;35(4):307–15.
11. Australian regulation of over-the-counter medicines 2016.[https://www.tga.
gov.au/node/4206]. Accessed 3 June 2016.
12. Peterson AM, Kelly WN. Managing pharmacy practice: principles, strategies.
In: And systems: CRC press; 2004.
13. Lombardi C, Musicco E, Rastrelli F, Bettoncelli G, Passalacqua G, Canonica GW.
The patient with rhinitis in the pharmacy. A cross-sectional study in real life.
Asthma Research and Practice. 2015;1(1):1.
14. Brass EP. Changing the status of drugs from prescription to over-the-counter
availability. N Engl J Med. 2001;345(11):810–6.
15. Holman H, Lorig K. Patient self-management: a key to effectiveness and
efficiency in care of chronic disease. Public Health Rep. 2004;119(3):239.
16. Cheong LH, Armour CL, Bosnic-Anticevich SZ. Primary health care teams
and the patient perspective: a social network analysis. Res Soc Adm Pharm.
2013;9(6):741–57.
17. Kuehl BL, Abdulnour S, O'Dell M, Kyle TK. Understanding the role of the
healthcare professional in patient self-management of allergic rhinitis. SAGE
Open Med. 2015;3:2050312115595822.
18. Bousquet J, van Cauwenberge P, Khaltaev N. ARIA in the pharmacy:
management of allergic rhinitis symptoms in the pharmacy - allergic rhinitis
and its impact on asthma. Allergy. 2004;59(4):373–87.
19. Hardon A, Hodgkin C. How to investigate the use of medicines by
consumers. In: How to investigate the use of medicines by consumers.
Geneva: EDN; 2004.
20. Nolte H, Nepper-Christensen S, Backer V. Unawareness and undertreatment
of asthma and allergic rhinitis in a general population. Respir Med.
2006;100(2):354–62.
21. Small P, Kim H. Allergic rhinitis. Allergy Asthma Clin Immunol. 2011;7(suppl 1):S3.
22. Champion VL, Skinner CS. The health belief model. Health behavior and
health education: theory, research, and. Practice. 2008;4:45–65.
23. Paudyal P, Capel-Williams GM, Griffiths E, Theadom A, Frew AJ, Smith HE.
Readability, presentation and quality of allergy-related patient information
leaflets; a cross sectional and longitudinal study. In: Journal of Allergy &
Therapy. 2015; 2015.
24. Baena-Cagnani CE, Canonica GW, Zaky Helal M, Gomez RM, Compalati E,
Zernotti ME, Sanchez-Borges M, Morato Castro FF, Murrieta Aguttes M,
Lopez-Garcia A, et al. The international survey on the management of
allergic rhinitis by physicians and patients (ISMAR). World Allergy Organ J.
2015;8(1):10.
25. Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S,
Brignardello-Petersen R, Canonica GW, Casale T, Chavannes NH, et al.
Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines–2016 Revision.
J Allergy Clin Immunol. 2017;140(4):950–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Tan et al. Asthma Research and Practice  (2017) 3:8 Page 8 of 8
